Endpoint Validation Study (0524A-015)

PHASE2CompletedINTERVENTIONAL

Enrollment

165

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions

Flushing

Interventions

DRUG

MK0524A, /Duration of Treatment : 8 Weeks

DRUG

Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00533676 - Endpoint Validation Study (0524A-015) | Biotech Hunter | Biotech Hunter